Novel Hydroisobenzofurans for Anticancer and/or Antibiotic Applications

Description:

Naturally occurring products known as 2, 11 cyclized cembranoids have been shown to inhibit the growth of KB3 nasopharyngeal carcinoma. KB3 cells are the standard cancer cell line used to test for chemotherapy effectiveness. University scientists have developed a unique synthesis process to create bicyclic hydroisobenzofurans, the beneficial compounds that are naturally occurring in 2, 11 cyclized cembranoids. These specific compounds have not previously been investigated for anticancer or antibiotic applications. To date testing has shown inhibition of growth of 50% of the KB3 cancer test cells at a concentration of the chemical compound of 3 micromolar.

To see and read the issued patent, click the following link http://vpred.uark.edu/documents/techventures/tech_docs/us8450366.pdf

To read a published article about the technology, click the following link http://vpred.uark.edu/documents/techventures/tech_docs/nihms353537.pdf

 

 

 

 

Patent Information:
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Non-Provisional United States 12/803,611 8,450,366 6/30/2010 5/28/2013  
For Information, Contact:
Mark Swaney
Technology Licensing Officer
University of Arkansas
479-575-7243
mswaney@uark.edu
Inventors:
Matthias McIntosh
Keywords:
© 2017. All Rights Reserved. Powered by Inteum